Naxitamab
Modify Date: 2024-01-21 21:43:59
Naxitamab structure
|
Common Name | Naxitamab | ||
|---|---|---|---|---|
| CAS Number | 1879925-92-4 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of NaxitamabNaxitamab (Hu3F8) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers[1]. |
| Name | Naxitamab |
|---|
| Description | Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Naxitamab (Hu3F8; 72 h) has cytotoxicity against neuroblastoma cell line LAN-1 with an EC50 value of 5.1 μg/mL[1]. Naxitamab (0.1-1 μg/mL; 4 h; peripheral blood mononuclear cells (PBMC) and polymorphonuclear leukocytes (PMN)) has antibody-dependent cell-mediated cytotoxic effects (ADCC)[1]. |
| In Vivo | Naxitamab (Hu3F8; 100 mg/kg; i.v.; twice a week, for 4 weeks; athymic nude mice with LAN-1 xenografts) inhibits tumor growth in neuroblastoma xenografts[1]. Animal Model: Female athymic nude mice with LAN-1 xenografts[1] Dosage: 100 mg/kg Administration: Intravenous injection; twice a week, for 4 weeks Result: Inhibited tumor growth and prolonged the survival time. |
| References |
[2]. Markham A. Naxitamab: First Approval. Drugs. 2021 Feb;81(2):291-296. |
| No Any Chemical & Physical Properties |